-
公开(公告)号:EP0811065B1
公开(公告)日:2006-09-13
申请号:EP96907112.5
申请日:1996-02-21
申请人: IMMUNEX CORPORATION
IPC分类号: C12N15/24 , C07K14/54 , C07K16/24 , A61K39/395 , A61K38/20 , A61K47/48 , C12N1/21 , C12N1/19
CPC分类号: C07K16/244 , A61K38/00 , A61K2039/505 , C07K14/5443
摘要: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R alpha -subunit and that are incapable of transducing a signal through either the beta - or gamma -subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the beta - or gamma -subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
-
公开(公告)号:EP0772624B1
公开(公告)日:2000-09-13
申请号:EP94915781.2
申请日:1994-04-06
申请人: IMMUNEX CORPORATION
发明人: GRABSTEIN, Kenneth, H. , ANDERSON, Dirk, M. , EISENMAN, June, R. , RAUCH, Charles , FUNG, Victor
CPC分类号: C07K14/5443 , A61K38/00 , Y02A50/463
摘要: There is disclosed a mammalian epithelium-derived T-cell factor ("ETF") polypeptide referred to herein as Interleukin-15 ("IL-15"), derivatives thereof, DNA sequences, recombinant DNA molecules and transformed host cells that produce IL-15 polypeptides. More particularly, this invention provides isolated mammalian IL-15 polypeptides and derivatives thereof that regulate events in T-lymphocyte proliferation.
-
公开(公告)号:EP0772624A1
公开(公告)日:1997-05-14
申请号:EP94915781.0
申请日:1994-04-06
申请人: IMMUNEX CORPORATION
发明人: GRABSTEIN, Kenneth, H. , ANDERSON, Dirk, M. , EISENMAN, June, R. , RAUCH, Charles , FUNG, Victor
CPC分类号: C07K14/5443 , A61K38/00 , Y02A50/463
摘要: There is disclosed a mammalian epithelium-derived T-cell factor ("ETF") polypeptide referred to herein as Interleukin-15 ("IL-15"), derivatives thereof, DNA sequences, recombinant DNA molecules and transformed host cells that produce IL-15 polypeptides. More particularly, this invention provides isolated mammalian IL-15 polypeptides and derivatives thereof that regulate events in T-lymphocyte proliferation.
-
公开(公告)号:EP0335900A1
公开(公告)日:1989-10-11
申请号:EP88900410.0
申请日:1987-12-04
申请人: IMMUNEX CORPORATION
发明人: ANDERSON, Dirk, M. , COSMAN, David, J. , DEELEY, Michael, C. , GRABSTEIN, Kenneth, H. , PRICE, Virginia, L.
IPC分类号: G10L11 , A61K35 , A61K38 , A61P31 , A61P35 , C07K1 , C07K14 , C12N15 , C12P21 , G10L15 , C12R1
CPC分类号: G10L15/063 , A61K38/00 , C07K14/395 , C07K14/5406 , C07K2319/02 , C12N5/0636 , C12N2501/2302 , C12N2501/2304
摘要: Protéines analogues recombinantes humaines mutantes biologiquement actives IL-4 (rhIL-4) dans lesquelles les sites de glycosylation à liaison N ont été inactivés.
-
公开(公告)号:EP0811065B2
公开(公告)日:2010-06-30
申请号:EP96907112.5
申请日:1996-02-21
申请人: Immunex Corporation
IPC分类号: C12N15/24 , C07K14/54 , C07K16/24 , A61K39/395 , A61K38/20 , A61K47/48 , C12N1/21 , C12N1/19
CPC分类号: C07K16/244 , A61K38/00 , A61K2039/505 , C07K14/5443
-
公开(公告)号:EP0831902A1
公开(公告)日:1998-04-01
申请号:EP96915558.0
申请日:1996-05-07
申请人: IMMUNEX CORPORATION
CPC分类号: C07K14/5443 , A61K38/30 , A61K38/20 , A61K2300/00
摘要: Compositions and methods for stimulating muscle growth or differentiation in a vertebrate are disclosed. Such compositions include a muscle-trophic amount of interleukin-15 and can be used to treat a variety of conditions including disuse atrophy, wasting, various age-related disorders, secondary effects of diabetes, including glucose-intolerance, as well as muscular dystrophy, rhabdomyosarcoma and congestive heart failure. The compositions and methods of the invention find agricultural use in increasing the efficiency of meat and milk production of farm animals.
-
公开(公告)号:EP0811065A1
公开(公告)日:1997-12-10
申请号:EP96907112.0
申请日:1996-02-21
申请人: IMMUNEX CORPORATION
IPC分类号: C12N15 , A61K38 , A61K39 , A61K47 , A61P37 , C07K14 , C07K16 , C07K19 , C12N1 , C12P21 , C12R1
CPC分类号: C07K16/244 , A61K38/00 , A61K2039/505 , C07K14/5443
摘要: Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or η-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or η-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
-
-
-
-
-
-